Company
Headquarters: Redwood City, CA, United States
Employees: 205
CEO: Dr. Reza Zadno Ph.D.
| Company | Market Cap (USD) |
|---|---|
| Abbott | $216.15 B |
| Boston Scientific Corporation | $140.40 B |
| Stryker | $133.15 B |
| Medtronic | $123.20 B |
| Edwards Lifesciences Corporation | $50.10 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $136.2 M |
| EBITDA | $-105,363,000 |
| Gross Profit TTM | $71.0 M |
| Profit Margin | -77.76% |
| Operating Margin | -67.82% |
| Quarterly Revenue Growth | 83.30% |
PROCEPT BioRobotics Corp has the following listings and related stock indices.
Stock: NASDAQ: PRCT